AgingResearch.NewsJoin free

Protego Biopharma

CompanyAustralia

Protego Biopharma develops one asset, in phase 1 (PROT-001). Mostly small molecule acting on proteostasis; based in Australia.

1
Asset
Furthest stage
Phase 1
Raised
US$214.9m
1
Trial
0
Signals

Pipeline

1

  • PROT-001

    Small molecule pharmacologic chaperone enhancing protein folding and proteostasis.

    Phase 1, Small molecule, Proteostasis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Funding rounds and grants4
  • People10
  • Signals2
  • Similar companies6

Intelligence